Kenvue Inc. (NYSE:KVUE) Receives $24.42 Consensus Price Target from Analysts

Kenvue Inc. (NYSE:KVUE) has been assigned a consensus rating of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $24.42.

KVUE has been the subject of several research reports. Barclays lowered their price objective on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, April 14th. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Finally, Citigroup raised their price target on Kenvue from $21.00 to $22.00 and gave the company a “neutral” rating in a research note on Monday, April 14th.

Kenvue Stock Performance

Kenvue stock opened at $23.98 on Tuesday. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The company’s 50-day moving average is $23.09 and its 200 day moving average is $22.51. The firm has a market capitalization of $46.01 billion, a P/E ratio of 45.25, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Research analysts forecast that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Wednesday, May 14th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 annualized dividend and a yield of 3.42%. Kenvue’s payout ratio is presently 154.72%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB raised its position in Kenvue by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company’s stock worth $15,846,000 after buying an additional 21,222 shares during the last quarter. Alberta Investment Management Corp raised its holdings in shares of Kenvue by 23.2% during the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock worth $12,445,000 after purchasing an additional 109,700 shares during the last quarter. Longbow Finance SA lifted its position in Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company’s stock valued at $5,990,000 after purchasing an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in Kenvue by 143.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company’s stock valued at $1,023,000 after purchasing an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. grew its position in Kenvue by 1.4% during the 4th quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company’s stock worth $26,754,000 after purchasing an additional 17,466 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.